Sorriso Pharmaceuticals Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Early Stage VC
- Investors
-
5
Sorriso Pharmaceuticals General Information
Description
Developer of disease-modifying antibodies designed for the treatment of inflammatory diseases, including Crohn's disease and ulcerative colitis. The company develops potent antibodies that can be delivered orally, providing clinical impacts similar to those of injectable antibody therapeutics, enabling healthcare providers to relieve the treatment burden for patients who rely on drugs that can only be administered via injections.
Contact Information
Website
www.sorrisopharma.comCorporate Office
- 9295 South 1300 East
- Suite 3
- Sandy, UT 84094
- United States
Corporate Office
- 9295 South 1300 East
- Suite 3
- Sandy, UT 84094
- United States
Sorriso Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 01-May-2024 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series A) | 22-Dec-2021 | Completed | Clinical Trials - Phase 2 | |||
| 1. Accelerator/Incubator | Completed | Clinical Trials - Phase 2 |
Sorriso Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Sorriso Pharmaceuticals Patents
Sorriso Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026178289-A1 | Il-23 and tnf-alpha inhibitors for use in autoimmune and inflammatory disorders | Pending | 21-Feb-2025 | ||
| WO-2025076251-A1 | Dosages of il-23 and tnf-alpha inhibitors for use in autoimmune and inflammatory disorders | Inactive | 05-Oct-2023 | ||
| EP-4750804-A1 | Il-23 and tnf-alpha induction treatment for autoimmune and inflammatory disorders | Pending | 26-Jul-2023 | ||
| US-20260209332-A1 | Il-23 and tnf-alpha induction treatment for autoimmune and inflammatory disorders | Pending | 26-Jul-2023 | ||
| WO-2025024723-A1 | Il-23 and tnf-alpha induction treatment for autoimmune and inflammatory disorders | Inactive | 26-Jul-2023 | C07K16/241 |
Sorriso Pharmaceuticals Signals
Sorriso Pharmaceuticals Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Biovision Ventures | Venture Capital | Minority | ||
| Lundbeckfonden BioCapital | Venture Capital | Minority | ||
| New Enterprise Associates | Venture Capital | Minority | ||
| Pappas Capital | Venture Capital | Minority | ||
| Magnify | Accelerator/Incubator |
Sorriso Pharmaceuticals FAQs
-
When was Sorriso Pharmaceuticals founded?
Sorriso Pharmaceuticals was founded in 2020.
-
Where is Sorriso Pharmaceuticals headquartered?
Sorriso Pharmaceuticals is headquartered in Sandy, UT.
-
What is the size of Sorriso Pharmaceuticals?
Sorriso Pharmaceuticals has 8 total employees.
-
What industry is Sorriso Pharmaceuticals in?
Sorriso Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Sorriso Pharmaceuticals a private or public company?
Sorriso Pharmaceuticals is a Private company.
-
What is Sorriso Pharmaceuticals’s current revenue?
The current revenue for Sorriso Pharmaceuticals is .
-
How much funding has Sorriso Pharmaceuticals raised over time?
Sorriso Pharmaceuticals has raised $31M.
-
Who are Sorriso Pharmaceuticals’s investors?
Biovision Ventures, Lundbeckfonden BioCapital, New Enterprise Associates, Pappas Capital, and Magnify have invested in Sorriso Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process